

Revision date: 04-Jan-2007 Version: 1.1 Page 1 of 6

1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING

Pfizer Inc
Pfizer Inc
Pfizer Pharmaceuticals Group
Ramsgate Road
235 East 42nd Street
Sandwich, Kent
New York, New York 10017
CT13 9NJ
1-212-573-2222
United Kingdom
+00 44 (0)1304 616161

Emergency telephone number: Emergency telephone number:

Material Name: Daunorubicin hydrochloride for injection

Trade Name: Daunoblastin Chemical Family: Mixture

Intended Use: Pharmaceutical product used as Antineoplastic, antibiotic agent

2. COMPOSITION/INFORMATION ON INGREDIENTS

Hazardous

Ingredient	CAS Number	EU EINECS List	%
Daunorubicin Hydrochloride	23541-50-6	245-723-4	<0.5

Ingredient	CAS Number	EU EINECS List	%
Water for injection	7732-18-5	231-791-2	*
Sodium chloride	7647-14-5	231-598-3	*

Additional Information: * Proprietary

Ingredient(s) indicated as hazardous have been assessed under standards for workplace

safety.

3. HAZARDS IDENTIFICATION

Appearance: Liquid Signal Word: WARNING

Statement of Hazard: May cause adverse effects on blood forming organs.

Suspected of damaging the unborn child. Suspected of causing genetic defects.

Suspected of causing cancer.

May cause cardiovascular system effects

Additional Hazard Information:

Short Term: Harmful if swallowed (based on animal data) . Drugs of this class have been associated with

rare, but potentially serious cardiac events. These events have not been observed from occupational exposures, however, those with preexisting cardiovascular illnesses may be at

increased risk from exposure.

Long Term: Repeat-dose studies in animals have shown a potential to cause adverse effects on testes

and the developing fetus.

Known Clinical Effects: Effects on blood and blood-forming organs have also occurred.

EU Indication of danger: Not classified

Material Name: Daunorubicin hydrochloride for injection Page 2 of 6
Revision date: 04-Jan-2007 Version: 1.1

Version date. 04-0an-2007

Note: This document has been prepared in accordance with standards for workplace safety, which

require the inclusion of all known hazards of the active substance or its intermediates regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your

workplace.

4. FIRST AID MEASURES

Eye Contact: Immediately flush eyes with water for at least 15 minutes. If irritation occurs or persists, get

medical attention.

Skin Contact: Remove clothing and wash affected skin with soap and water. If irritation occurs or persists,

get medical attention.

Ingestion: Do not induce vomiting unless directed by medical personnel. Never give anything by mouth to

an unconscious person. Get medical attention.

Inhalation: Remove to fresh air. If not breathing, give artificial respiration. Get medical attention.

5. FIRE FIGHTING MEASURES

Extinguishing Media: Use carbon dioxide, dry chemical, or water spray.

Hazardous Combustion Products: Formation of toxic gases is possible during heating or fire.

Fire Fighting Procedures: During all fire fighting activities, wear appropriate protective equipment, including self-

contained breathing apparatus.

Fire / Explosion Hazards: Not applicable

6. ACCIDENTAL RELEASE MEASURES

Health and Safety Precautions: Personnel involved in clean-up should wear appropriate personal protective equipment (see

Section 8). Minimize exposure.

Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean spill

area thoroughly.

Measures for Environmental

Protections:

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to

avoid environmental release.

Additional Consideration for Large

Spills:

Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

Material Name: Daunorubicin hydrochloride for injection

Revision date: 04-Jan-2007 Version: 1.1

General Handling: Avoid contact with eyes, skin and clothing. Avoid breathing vapor or mist. Use appropriate

ventilation. When handling, use proper personal protective equipment as specified in Section

Page 3 of 6

8. Wash thoroughly after handling.

Storage Conditions: Store as directed by product packaging.

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Daunorubicin Hydrochloride

Pfizer OEL TWA-8 Hr: 0.1 ug/m³

The exposure limit(s) listed for solid components are only relevant if dust or mist may be generated.

Analytical Method: Analytical method available for daunorubicin. Contact Pfizer Inc for further information.

Engineering Controls: Engineering controls should be used as the primary means to control exposures. Local

exhaust ventilation is required unless used in a closed system.

Personal Protective Equipment:

Hands: Chemical protective gloves **Eyes:** Safety glasses or goggles

Skin: Wear protective clothing with long sleeves to avoid skin contact. Wash hands and arms

thoroughly after handling this product.

Respiratory protection: If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate

respirator with a protection factor sufficient to control exposures to below the OEL.

9. PHYSICAL AND CHEMICAL PROPERTIES:

Physical State:LiquidColor:ColorlessMolecular Formula:MixtureMolecular Weight:Mixture

10. STABILITY AND REACTIVITY

Stability: Stable under normal conditions of use.

Conditions to Avoid: None known

Incompatible Materials: As a precautionary measure, keep away from strong oxidizers.

11. TOXICOLOGICAL INFORMATION

General Information: The information included in this section describes the potential hazards of the individual

ingredients.

Acute Toxicity: (Species, Route, End Point, Dose)

Daunorubicin Hydrochloride

Rat Oral LD 50 336 mg/kg Rat Intravenous LD50 13 mg/kg Rat Intraperitoneal LD50 20 mg/kg Mouse Oral LD50 205 mg/kg Intravenous LD50 Mouse 8.6 mg/kg

Sodium chloride

Page 4 of 6

Material Name: Daunorubicin hydrochloride for injection

Revision date: 04-Jan-2007 Version: 1.1

Rat Oral LD50 3000 mg/kg Mouse Oral LD 50 4000 mg/kg

<u>Irritation / Sensitization: (Study Type, Species, Severity)</u>

Sodium chloride

Eye Irritation Rabbit Moderate Skin Irritation Rabbit Mild

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Sodium chloride

10 Day(s) Rat Oral 12500 mg/kg LOAEL Kidney, Ureter, Bladder

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

Daunorubicin Hydrochloride

Embryo / Fetal Development Rabbit Oral 0.05 mg/kg/day LOAEL Teratogenic, Fetotoxicity

Embryo / Fetal Development Rat Oral 4 mg/kg/day LOAEL Teratogenic

Embryo / Fetal Development Rabbit Intravenous 1.5 mg/kg LOAEL Fetotoxicity, Fertility

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Daunorubicin Hydrochloride

Bacterial Mutagenicity (Ames) Salmonella Positive In Vitro Cytogenetics Human Lymphocytes Positive In Vivo Micronucleus Not applicable Positive

Carcinogen Status: See below

Daunorubicin Hydrochloride

IARC: 2B - Possibly Carcinogenic to Humans

12. ECOLOGICAL INFORMATION

Environmental Overview: Environmental properties have not been investigated. Releases to the environment should be

avoided.

13. DISPOSAL CONSIDERATIONS

Disposal Procedures: Dispose of waste in accordance with all applicable laws and regulations.

14. TRANSPORT INFORMATION

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

Page 5 of 6

Material Name: Daunorubicin hydrochloride for injection

Revision date: 04-Jan-2007 Version: 1.1

15. REGULATORY INFORMATION

EU Indication of danger: Not classified

OSHA Label:

WARNING

May cause adverse effects on blood forming organs. Suspected of damaging the unborn child. Suspected of causing genetic defects. Suspected of causing cancer. May cause cardiovascular system effects

Canada - WHMIS: Classifications

WHMIS hazard class:

Class D, Division 2, Subdivision A



Daunorubicin Hydrochloride

California Proposition 65 Listed: Developmental toxicity

Australia (AICS): Present EU EINECS List 245-723-4

Water for injection

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

Fresent

EU EINECS List

231-791-2

Sodium chloride

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

EU EINECS List

Present
231-598-3

16. OTHER INFORMATION

Reasons for Revision: Updated Section 3 - Hazard Identification. Updated Section 6 - Accidental Release Measures.

Updated Section 8 - Exposure Controls / Personal Protection. Updated Section 10 - Stability

and Reactivity. Updated Section 13 - Disposal Considerations.

Prepared by: Corporate Occupational Toxicology & Hazard Assessment

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied.

Material Name: Daunorubicin hydrochloride for injection Revision date: 04-Jan-2007 Page 6 of 6 Version: 1.1